A Cohort Study on Response of T2DM Patients to Oral Antidiabetics and their Association with CYP2C9*3 Gene Polymorphism (rs1057910) in Khyber Pakhtunkhwa, Pakistan | [Pakistan Journal of Zoology • 2024]

Author(s):

1. Iram Alam Sthanadar: Department of Zoology, Islamia College University,Peshawar,Pakistan

2. Muhammad Zahid: Department of Zoology, Islamia College University,Peshawar,Pakistan

3. Sami Siraj: Khyber Medical University,Peshawar,Pakistan

4. Omar Malik: Khyber Medical University,Peshawar,Pakistan

Abstract:

Type 2 diabetes mellitus (T2DM) is an important public health problem all over the world, afecting approximately 417 million adults which is expected to reach to 592 million by the year 2035 globally. Metformin, sulfonylureas (SFUs) are widely used oral anti-diabetic drugs metabolized by cytochrome P450 belonging to family 2 subfamily C member 9 (CYP2C9). CYP2C9 has shown better glycemic control and reduced the treatment failure rates compared to metformin and its combination therapy. To study the association of CY2PC9 gene variant rs1057910 in T2DM patients of Khyber Pakhtunkhwa (KP) origin, the cohort study was conducted for a period of 12 months including 150 patients receiving metformin, glimepiride and its combination therapy. Purposive sample technique was used for sample collection. Data collection was done by proper questionnaire. DNA was extracted from 200 µL of whole blood samples obtained from the patients by using the Wiz-Prep DNA extraction kit (Wiz-Prep no. W54100). Sanger sequencing was used for genetic analysis. Data analysis was done by using IBMS-KMU SPSS 23 version. The Hardy-Weinberg equilibrium for T2DM subjects was determined using an online HWE calculator. The rs1057910 polymorphism in CY2PC9 gene responsible for drug metabolism was analyzed which showed that our population has high frequency of major allele CC which confirmed that patients receiving metformin, glimepiride and its combination therapy were efective for glycemic control through-out in a 12 months cohort with a p value of <0.0001. The SNP rs1057910 in CYP2C9 was inconsistent with H.W equilibrium and shows disequilibrium in our population. The study found a modest but non-significant efect of the CYP2C9*3 rs1057910 polymorphism on susceptibility to type 2 diabetes in KP Pakistan, highlighting the need for further research on gene-environment and gene-gene interactions.

Page(s): 2565-2572

DOI: 10.17582/journal.pjz/20231226112338

Published: Journal: Pakistan Journal of Zoology, Volume: 56, Issue: 6, Year: 2024

Keywords:

Metformin , T2DM , glimepiride , CYP2C9 gene rs1057910 and Responders

References:

[1] Ahluwalia T.S.,Kilpeläinen T.O.,Singh S.,Rossing P. .2019 .Novel biomarkers for type 2 diabetes. Frontiers Media SA. , : .

[2] Ahmed S.,Altaf N.,Ejaz M.,Altaf A.,Amin A.,Janjua K.,Khan A.U.,Imran I.,Khan S. .2020 .Variations in the frequencies of polymorphisms in the CYP2C9 gene in six major ethnicities of Pakistan. Sci. Rep, 10 : 19370.

[3] Alwin R.A.,Al-Dawish A.M.,Braham R.,Musallam A.M.,Al-Hayek A.A.,Al-Kahtany H.N. .2017 .Type 2 diabetes mellitus in Saudi Arabia: Major challenges and possible solutions. Curr. Diab. Rev., 13 : 59-64.

[4] Bowe B.,Xie Y.,Li T.,Yan Y.,Xian H.,Al-Aly Z. .2018 .The 2016 global and national burden of diabetes mellitus attributable to PM2 5 air pollution. Lancet Planet. Hlth., 5196(18) : 30140-2.

[5] Brunetti L.,Kalabalik J. .2012 .Management of type-2 diabetes mellitus in adults: Focus on individualizing non-insulin therapies. Pharm, 37 : 687.

[6] Cario E. .2016 .Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity. Curr. Opin. Supp. Palliat. Care, 10 : 157-164.

[7] Castelán-Martínez O.,Hoyo-Vadillo C.,Bazán-Soto T.,Cruz M.,Tesoro-Cruz E.,ValladaresSalgado E. .2018 .3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide. J. clin. Pharm, 43 : 768-774.

[8] Chamboko C.R.,Veldman W.,Tata R.B.,Schoeberl B.,Tastan B.Ö. .2023 .Human cytochrome P450 1, 2, 3 families as pharmacogenes with emphases on their antimalarial and antituberculosis drugs and prevalent African alleles. Int. J. mol. Sci, 24 : 3383.

[9] Goldman-Levine J.D. .2011 .Beyond metformin: Initiating combination therapy in patients with type 2 diabetes mellitus. Pharmacother. J. Hum. Pharmacol. Drug Ther, 31 : 44S-53S.

[10] Holstein A.,Beil W.,Kovacs P. .2012 .CYP2C metabolism of oral antidiabetic drugs-impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Exp. Opin. Drug Metab. Toxicol., 8 : 1549-1563.

[11] Iqbal M.,Gill P.,Azam I.,Iqbal R. .2021 .Diabetic dyslipidemia and type 2 diabetes mellitus as early as six weeks post-partum: A nested case control study. Int. J. Commun. Med, 8 : 2394-6040.

[12] Jan A.,Saeed M.,Mothana R.A.,Muhammad T.,Rahman N.,Alanzi A.R.,Akbar R. .2023 .Association of CYP2C9* 2 Allele with sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus patients: A pharmacogenetic study in Pakistani Pashtun population. Biomedicines, 11 : 2282.

[13] Kim S.H.,Kim D.H.,Byeon J.Y.,Kim Y.H.,Kim D.H.,Lim H.J.,Lee C.M.,Whang S.S.,Choi C.I.,Bae J.W. .2017 .Efects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Arch. Pharm. Res., 40 : 382-390.

[14] Kirchheiner J.,Roots I.,Goldammer M.,Rosenkranz B.,Brockmöller J. .2005 .Efect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: Clinical relevance. Clin. Pharmacokinet, 44 : 00003088-1225.

[15] Liu Z.,Feng Y.,Zhao H.,Hu J.,Chen Y.,Liu D.,Wang H.,Zhu X.,Yang H.,Shen Z. .2023 .Pharmacokinetics and tissue distribution of Ramulus mori (Sangzhi) alkaloids in rats and its efects on liver enzyme activity. Front, 14 : 1136772.

[16] Liu Z.,Fu C.,Wang W.,Xu B. .2010 .Prevalence of chronic complications of type 2 diabetes mellitus in outpatients-a cross-sectional hospital based survey in urban China. Hlth. Qual. Life Outcomes, 8 : 1477-9.

[17] Muhammad S.D.,Khan H.,Hussain M.,Zeb T.F.,Kumar D.,Rahi R.,Asif M.,Balooch A.A. .2020 .Pharmacogenetics of sulfonylurea: Presence of CYP2C9* 2, CYP2C9* 3 and a novel allele, CYP2C9* 61, in Type 2 diabetes patients under sulfonylurea therapy. Pak. J. Pharm. Sci., 33 : 1771-1777.

[18] Perwitasari D.A.,Faridah I.N.,Maliza R.,Dania H.,Irham L.M. .2021 .Identification of SNP rs1799853 of CYP2C9 gene and blood sugar levels in diabetic patients. Asian J. Pharmacol. Toxicol., 9 : 1.

[19] Powers A.C.,D'alessio A.C.,McGraw-Hill A.C. .2011 .Goodman and Gilman's, The Pharmacological Basis of Therapeutics. , : 1237-271.

[20] Proks P.,Reimann F.,Green N.,Gribble F.,Ashcroft F. .2007 .Sulfonylurea stimulation of insulin secretion. Diabetes, 51 : S368-S376.

[21] Roosan M.R.,Sharma A. .2021 .CYP2C9 polymorphism and use of oral nonsteroidal antiinflammatory drugs. US Pharm, 54 : 23-30.

[22] Salam R.F.A.,Zeyada R.,Osman N.A. .2014 .Efect of CYP2C9 gene polymorphisms on response to treatment with sulfonylureas in a cohort of Egyptian type 2 diabetes mellitus patients. Comp. clin. Pathol, 23 : 341-346.

[23] Soldin O.P.,Chung S.H.,Mattison D.R. .2011 .Sex diferences in drug disposition. BioMed. Res. Int, : .

[24] Suzuki K.,Yanagawa T.,Shibasaki T.,Kaniwa N.,Hasegawa R.,Tohkin M. .2005 .Efect of CYP2C9 genetic polymorphisms on the eficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diab. Res. clin. Pract, 09 : 148-154.

[25] Van Dalem J.,Brouwers M.C.,Stehouwer C.D.,Krings A.,Leufkens H.G.,Driessen J.H.,De Vries F.,Burden A.M. .2016 .Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: Population based cohort study. Br. med. J., 354 : 1-7.

[26] Wang Y.H.,Pan P.P.,Dai D.P.,Wang S.H.,Geng P.W.,Cai J.P.,Hu G.X. .2013 .Efect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro. Xenobiotica, 8 : 20007-275.

[27] Weise A.,Prause S.,Eidens M.,Weber M.,Kann P.,Forst T.,Pfützner A. .2010 .Prevalence of CYP450 gene variations in patients with type 2 diabetes. Clin. Lab, 56 : 311-318.

[28] Yin T.,Maekawa K.,Kamide K.,Saito Y.,Hanada H.,Miyashita K.,Kokubo Y.,Akaiwa Y.,Otsubo R.,Nagatsuka K. .2008 .Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive efects of losartan. Hypertens. Res., 31 : 1549-1557.

[29] Zanger U.,Schwab M. .2012 .Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol, 12 : 103-141.

[30] Zhou S.F.,Zhou Z.W.,Huang M. .2009 .Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology, 08 : 165-188.

Citations

Downloads

Views